Dr. Gaurav Shah MD

Professor of Ophthalmology, WASHINGTON UNIVERSITY MEDICAL CENTER

GLG News by Dr. Gaurav Shah MD, Professor of Ophthalmology

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

JSM 6427: the new face of armd therapy

July 30, 2007

Analysis of:FDA Accepts Jerini Ophthalmic's IND of JSM 6427 for the Treatment of AMD | www.pipelinereview.com

1. A molecule that allows on to stop neovascular armd to form from dry armd 2. A product with a potentially large market share compared to the current agents available 3. A compound that could have a sustained drug delivery module

PDT still a viable alternatvie

March 14, 2007

Analysis of:PDT more effective for myopic CNV in patients 55 years and younger, study finds | www.osnsupersite.com

PDT remains a viable option for patients with new blood vessels from high myopia. Despite the era of antivegf therapy PDT may be safer in these patients than repeated injection. This article yet again defies another area for the use of PDT. PDT will be continued to be complemented to the currently available therapies of antivegf for not only myopic degeneration, but also macular degeneration.

Laser to drusen trial

November 20, 2006

Analysis of:Laser Treatment Ineffective In Preventing Vision Loss In Early Age-Related Macular Degeneration | www.pharma-lexicon.com

It is not surprising that laser therapy is not effective for patients with macular degeneration. Initially there was a significant interest in this therapy, but as this well designed trial has shown us that thermal treatment is not the answer for dry ARMD. AREDS I and AREDS II are now the most important vitamin related studies with ARMD. The future for dry ARMD lies potentially with encapsulated compounds that may be delivered to the back of the eye for geographic atrophy. Currently the Anti-VEGF agents Lucentis and Avastin are the gold standard for wet ARMD. PDT in combination with these agents may be useful for decreasing the number in the injections involved.

Page : 11 to 3 of 3

Subscribe to Updates

By RSS